---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-048915"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:31:27.387761+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma Q1 net income $21.5M on warrant gain; cash $15.9M; CEO transition

## Summary
- Net income of $21.5M ($2.17 basic EPS) driven by $26.5M gain from warrant liability fair value change; revenue $57K.
- Cash and equivalents $15.9M as of Mar 31, 2025, down from $21.3M; runway into Q1 2026.
- Submitted FDA briefing package for tivoxavir marboxil (TXM) under Animal Rule; ratutrelvir briefing package planned Q2 2025.
- Iain Dukes named Interim CEO after retirement of Werner Cautreels; Jack Stover appointed Chairman.
- R&D expense $2.5M (+$0.6M YoY) on virology program; G&A $2.8M (-$0.6M YoY) on lower consulting fees.

## SEC filing metadata
- accession: 0001104659-25-048915
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925048915/0001104659-25-048915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925048915/tm2515069d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-048915
- JSON: https://secwatch.observer/filing/0001104659-25-048915.json
- Plain text: https://secwatch.observer/filing/0001104659-25-048915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.